Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens
Fig 5
Comparison of CD3+ T cells and Foxp3+CD3+ T cells between before and after intravesical BCG treatment.
The average cell numbers in a high-power field (HPF) of biopsy samples after BCG are calculated on the basis of the cell numbers in 2–5 HPFs of stroma areas in each specimen. The cell numbers before BCG are calculated in the TURBT specimens. (A) the number of CD3+ cells/HPF, (B) the number of Foxp3+CD3+ cells/HPF, (C) the percentage of Foxp3+CD3+ cells in CD3+ cells. Red: patients with recurrence (n = 4), black: patients without recurrence (n = 6). (A) The median (interquartile range) of the number of CD3+ T cells are 130.7 (179.5, 50.7–230.2) before BCG treatment and 200 (247.6, 794–327) after BCG treatment in 4 patients with recurrence (P = 0.25, Wilcoxon signed rank sum test). The median (interquartile range) numbers of CD3+ T cells are 58.4 (24.8, 42.7–67.5)/HPF before BCG treatment and 116.5 (89.2, 67.1–156.2)/HPF after BCG treatment in patients without recurrence (P = 0.219, Wilcoxon signed rank sum test). (b) The median (interquartile range) numbers of Foxp3+CD3+ T cells are 37.4 (52.3, 11.2–63.5) /HPF before BCG treatment and 40.3 (40.5, 18.3–58.8) /HPFs after BCG treatment in 4 patients with recurrence (P = 0.875, Wilcoxon signed rank sum test). The median (interquartile range) numbers of Foxp3+ CD3+ T cells are 15.3 (7.1, 8.6–15.7) /HPF before BCG treatment and 20.3 (10.9, 11.8–22.7) /HPF after BCG treatment in patients without recurrence (P = 0.438, Wilcoxon signed rank sum test). (c) The median (interquartile range) percentages of Foxp3+CD3+ T cells are 22.3% (2.8, 21.7–24.5%) before BCG treatment and 17.5% (5.6, 14.7–20.3%) after BCG treatment in 4 patients with recurrence (P = 0.25, Wilcoxon signed rank sum test). The median (interquartile range) percentages of Foxp3+CD3+ T cells are 19.7% (7.0, 16.4–23.4%) before BCG treatment and 15.3% (3.6, 13.3–16.9%) after BCG treatment in patients without recurrence (P = 0.156, Wilcoxon signed rank sum test).